vanoxerine has been researched along with Choreoathetosis Self-Mutilation Hyperuricemia Syndrome in 2 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasim, S | 1 |
| Jinnah, HA | 1 |
| Sivam, SP | 1 |
1 review available for vanoxerine and Choreoathetosis Self-Mutilation Hyperuricemia Syndrome
| Article | Year |
|---|---|
Dopamine, serotonin and tachykinin in self-injurious behavior.
Topics: Animals; Cocaine; Dopamine; Humans; Lesch-Nyhan Syndrome; Piperazines; Rats; Self-Injurious Behavior | 1996 |
1 other study available for vanoxerine and Choreoathetosis Self-Mutilation Hyperuricemia Syndrome
| Article | Year |
|---|---|
Pharmacologic thresholds for self-injurious behavior in a genetic mouse model of Lesch-Nyhan disease.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |